Advanced Oncotherapy (LSE:AVO) Cash-to-Debt : 0.04 (As of Jun. 2022)

View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Advanced Oncotherapy's cash to debt ratio for the quarter that ended in Jun. 2022 was 0.04.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Advanced Oncotherapy couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for Advanced Oncotherapy's Cash-to-Debt or its related term are showing as below:

LSE:AVO's Cash-to-Debt is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.935
* Ranked among companies with meaningful Cash-to-Debt only.

Advanced Oncotherapy Cash-to-Debt Historical Data

The historical data trend for Advanced Oncotherapy's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Advanced Oncotherapy Cash-to-Debt Chart

Advanced Oncotherapy Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

0.01

0.34

0.06

0.04

0.07

Advanced Oncotherapy Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Cash-to-Debt	Get a 7-Day Free Trial															0.13	0.04	0.01	0.07	0.04

Competitive Comparison of Advanced Oncotherapy's Cash-to-Debt

For the Medical Devices subindustry, Advanced Oncotherapy's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Oncotherapy's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Cash-to-Debt falls into.

Advanced Oncotherapy Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Advanced Oncotherapy's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.76	/	(10.771	+	42.584)
	=	0.07

Advanced Oncotherapy's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.507	/	(14.422	+	45.321)
	=	0.04

Advanced Oncotherapy (LSE:AVO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Advanced Oncotherapy Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Oncotherapy (LSE:AVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Tenterden Street, Third Floor, London, GBR, W1S 1TE

Website

https://www.avoplc.com

Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.